Global Research on Myelodysplastic Syndrome Market t

Global Myelodysplastic Syndrome Market 2015-2019 - Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with Myelodysplastic Syndrome Market in subject line and your contact details.

Read 81 Pages Report at http://www.reportsnreports.com/reports/461285-globalmyelodysplastic-syndrome-market-2015-2019.html .

Myelodysplastic syndrome is a group of hematologic disorders that arise in the bone marrow and spread into the blood. The syndrome is characterized by the inability of the hematopoietic cells produced in the bone marrow to attain maturity. Cytological dysplasia is a common feature of the syndrome, progressing to acute myeloid leukemia in about 30% of individuals with myelodysplastic syndrome. The disease is age-related, mostly affecting people aged 60 and above. Smoking, exposure to radiation, contact with chemicals such as benzene, genetic mutations, and chemotherapy can cause myelodysplastic syndrome.

The analysts forecast global myelodysplastic syndrome market to grow at a CAGR of 9.93% during the period 2015-2019.

Covered in this report This report covers the present scenario and the growth prospects of the global myelodysplastic syndrome market for 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used for treating myelodysplastic syndrome.

The report describes the market by region:   

Americas: The US, Canada, Mexico, and Brazil EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE APAC: Japan, China, Australia, Singapore, South Korea, and India

This report, Global Myelodysplastic Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Buy a copy of report @ http://www.reportsnreports.com/Purchase.aspx?name=461285 for US $2500.

Key vendors

Global Myelodysplastic Syndrome Market 2015-2019

  

Celgene Novartis Otsuka

Other prominent vendors                      

Acceleron Pharma Amgen Astellas Astex Actinium Pharmaceuticals Bellicum Pharmaceuticals BioLineRx Celator Pharmaceuticals Cornerstone Pharmaceuticals CTI BioPharma Eli Lilly Gamida Cell GlaxoSmithKline KaloBios Pharmaceuticals Kiadis Pharma Mirati Therapeutics Onconova Therapeutics Strategia Therapeutics Sumitomo Dainippon Pharma Sunesis Pharmaceuticals Targazyme TetraLogic Pharmaceuticals

Market driver 

Rise in aging population

Market challenge 

Use of off-label drugs

Market trend 

Rise in public awareness

Global Myelodysplastic Syndrome Market 2015-2019

Inquire for Discount at http://www.reportsnreports.com/contacts/Discount.aspx?name=461285 .

Key questions answered in this report 1.

2.

3.

4.

5.

6.

7.

What will the market size be in 2019 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

List of Exhibits Exhibit 01: Product offerings 02: Myelodysplastic syndrome: Risk factors Exhibit 03: Myelodysplastic syndrome: Signs and symptoms Exhibit 04: History of myelodysplastic syndrome classification system Exhibit 05: FAB classification system: Types of myelodysplastic syndrome Exhibit 06: WHO classification system: Types of myelodysplastic syndrome Exhibit 07: IPSS classification: Factors and score Exhibit 08: IPSS-R classification: Cytogenetic score Exhibit 09: IPSS-R classification: Score values Exhibit 10: IPSS-R classification: Risk categories and scores Exhibit 11: Diagnostic tests for myelodysplastic syndrome Exhibit 12: Myelodysplastic syndrome: Global incidence based on age 2007-2011 (years) Exhibit 13: Myelodysplastic syndrome: Incidence in US by race 2007-2011 Exhibit 14: Treatment options for myelodysplastic syndrome Exhibit 15: Chemotherapeutic agents Global Myelodysplastic Syndrome Market 2015-2019

Exhibit 16: Immunotherapy drugs Exhibit 17: Supportive therapy for myelodysplastic syndrome Exhibit 18: Drugs that received orphan designation for treatment of myelodysplastic syndrome Exhibit 19: Myelodysplastic syndrome: Drug pipeline Exhibit 20: Global myelodysplastic syndrome market ($ millions) Exhibit 21: Five forces analysis Exhibit 22: Global myelodysplastic syndrome market segmentation by drug class Exhibit 23: Global myelodysplastic syndrome market segmentation by route of administration Exhibit 24: Global myelodysplastic syndrome market segmentation by geography 2014 Exhibit 25: Myelodysplastic syndrome market in Americas 2014-2019 ($ millions) Exhibit 26: Myelodysplastic syndrome market in EMEA 2014-2019 ($ millions) Exhibit 27: Myelodysplastic syndrome market in APAC 2014-2019 ($ millions) Exhibit 28: Global myelodysplastic syndrome market segmentation by geography 2014-2019 ($ millions) Exhibit 29: Impact of drivers Exhibit 30: Impact of drivers and challenges Exhibit 31: Ranking of leading companies Exhibit 32: Celgene: YoY growth and revenue of VIDAZA 2012-2014 ($ millions) Exhibit 33: Celgene: YoY growth and revenue of REVLIMID 2012-2014 ($ billions) Exhibit 34: Celgene: Key takeaways Exhibit 35: Otsuka Holdings: Key takeaways Exhibit 36: Novartis: Key takeaways Exhibit 37: Celgene: Product segmentation by revenue 2014

Global Myelodysplastic Syndrome Market 2015-2019

Exhibit 38: Celgene: Product segmentation by revenue 2013 and 2014 Exhibit 39: Celgene: Geographical segmentation by revenue 2014 Exhibit 40: Novartis: Business segmentation by revenue 2014 Exhibit 41: Novartis: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 42: Novartis: Geographical segmentation by revenue 2014 Exhibit 43: Otsuka Holdings: Business segmentation by revenue 2014 Exhibit 44: Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 45: Otsuka Holdings: Geographical segmentation by revenue 2014 Browse All Reports on Pharmaceuticals About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

Global Myelodysplastic Syndrome Market 2015-2019